Califf’s Top Priorities For New Year: Misinformation And Evidence Generation

FDA Commissioner is ‘pretty excited’ about obtaining high quality evidence in the postmarket space, noting agency's collaboration with NIH. He cites need to address the low cost of generic drugs as a factor in drug shortages.